Should I Buy MPLT? MPLT 2026 Analysis

Should You Buy MapLight Therapeutics Inc (MPLT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

16.980

1 Day change

8.15%

52 Week Range

21.550

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: momentum is still bearish (MACD expanding negative) and there are no near-term catalysts in the provided news flow.
Bullish Wall Street setup (multiple Buy/Overweight initiations with $28–$34 targets) supports the longer-term story, but the tape does not confirm an immediate entry.
If you must act today, risk/reward is only attractive very close to support (~$16.46); at ~$17 you’re in the middle of the range with overhead pivot resistance at ~$17.80.

Technical Analysis

Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Trend/Momentum: MACD histogram -0.151 below zero and negatively expanding → bearish momentum is increasing.
RSI(6) = 36.27 → weak/near-oversold but not a confirmed reversal signal.
Moving averages: converging → consolidation/indecision; not a clean uptrend.
Key levels: Support S1 ~$16.46 (then S2 ~$15.63). Resistance pivot ~$17.80, then R1 ~$19.14.
Pattern-based forward view (provided): 60% chance of ~+0.65% next day, +1.76% next week, +8.1% next month → modest upside bias, but not strong enough to override current bearish MACD.

Positive Catalysts

- Strong analyst sentiment: multiple recent initiations/positive notes with Buy/Outperform/Overweight ratings and high price targets ($28–$34).
- Sector/peer read-through: BMY’s ADEPT-2 continuation was viewed by Stifel as a net positive read-through for the muscarinic space, with potential “upside risk/reward” for MPLT.
- Positioning: hedge funds and insiders show neutral activity (no notable selling pressure indicated).

Neutral/Negative Catalysts

- No news in the recent week → lack of immediate event-driven catalyst to force an upside breakout.
- Technicals are not supportive for an immediate buy: MACD is negative and worsening, and price is below the pivot (~$17.80).
- Clinical-stage financial profile (no revenue, ongoing losses) can keep the stock sentiment-driven and choppy without fresh trial milestones.
- No supportive signal from Intellectia modules today (no AI Stock Picker or SwingMax entry).

Financial Performance

Latest provided quarter: 2024/Q2.
Revenue: 0 (no operating revenue; consistent with clinical-stage biotech profile).
Net income: -$18.4M (loss).
EPS: -1.26.
Gross margin: 0.
Growth trend takeaway: financials reflect ongoing R&D burn rather than operating growth; the stock will likely trade on pipeline milestones and sentiment rather than quarter-to-quarter fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend is decisively positive: a cluster of initiations on 2025-11-21 (Leerink Outperform $30, Morgan Stanley Overweight $34, Stifel Buy $28, Jefferies Buy $32) followed by a supportive Stifel note on 2025-12-03 reiterating upside risk/reward.
Wall Street pros: large market opportunity, belief in “best-in-class potential”/differentiation (tolerability, dosing) for ML-007C-MA; muscarinic mechanism viewed as attractive.
Wall Street cons (implied): program risk remains (Phase 2 stage), and the space has execution/launch uncertainty (read-through from slower-than-expected Cobenfy launch and trial-conduct issues elsewhere in the space), which can cap near-term multiple expansion without clean data.

4 Analyst Rating

Wall Street analysts forecast MPLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MPLT is 31 USD with a low forecast of 28 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 15.700

Low

Averages

High

Current: 15.700

Low

Averages

High

Stifel

Paul Matteis

Buy

maintain

$28

AI Analysis

2025-12-03

Reason

Stifel

Paul Matteis

Price Target

$28

AI Analysis

2025-12-03

maintain

Buy

Reason

After Bristol Myers (BMY) announced this morning that the ADEPT-2 study of Cobenfy in in Alzheimer's disease psychosis will continue enrolling additional patients after a review identified irregularities due to trial conduct at some sites, Stifel analyst Paul Matteis contends that the study continuation has "grey implications, but at face is a win" for MapLight Therapeutics (MPLT) and overall this is a positive, though there are some lingering questions. For MapLight, the firm thinks there's a chance that their muscarinic drug has a wider therapeutic index in elderly subjects and the firm sees "an upside risk/reward" as the current valuation "arguably prices in very little ADP credit." Stifel has a Buy rating and $28 price target on MapLight shares, which are up $3.61, or 28%, to $16.50 in morning trading.

Leerink

Marc Goodman

Outperform

initiated

$30

2025-11-21

Reason

Leerink

Marc Goodman

Price Target

$30

2025-11-21

initiated

Outperform

Reason

Leerink analyst Marc Goodman initiated coverage of MapLight Therapeutics with an Outperform rating and $30 price target. The firm is bullish on the muscarinic space and says MapLight's lead asset ML-007C-MA has a potentially better clinical profile than Cobenfy. ML-007C-MA is in Phase 2 development for the treatment of Alzheimer's disease psychosis, which is a large market with significant unmet need, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MPLT

Unlock Now

MPLT Should I Buy

MPLT Should I Buy

Should You Buy MapLight Therapeutics Inc (MPLT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch